Stratified research as a clinical standard.
Our programs are structured along clinical differentiation features. In phytomedicine, patient groups are key development parameters: metabolism, comorbidities, polypharmacy, and everyday requirements change dosing windows, tolerability, and outcome targets.
We address these variances and everyday requirements through our methodological framework:
Submit a collaboration inquiry
TPP
Prototyping
Evidence pathway
Exemplary research matrix
Pediatrics (e.g., neurological indications)
In pediatric care, tolerability, clear dosing logic, and practice-oriented formulations are paramount - always adapted to the particular vulnerability of the developing organism.
- Safety focus: reduction of sedating effects and profiles with a low psychoactive load where clinically required
- Formulation: precise dose control and stable dosage forms to support adherence
- Evidence: endpoints and protocols adapted to pediatric requirements
Multimorbid geriatrics
Geriatric patients are often characterized by multimorbidity and polypharmacy. Development parameters include safety profiles, interactions, and conservative titration logic:
- Safety first: balance between sedation and fall risk; monitoring of relevant cognitive parameters
- Titration logic: conservative dosing regimens with altered metabolic conditions
- Everyday suitability: simple delivery concepts that reduce application errors
Adults (e.g., pain medicine / functional requirements)
The focus is on restoring everyday functionality, quality of life, and ability to work through controllable effect profiles and reproducible use.
- Functionality: predictable effect profiles taking cognitive demands into account
- Reproducibility: consistent profiles as the basis for comparable use
- Evidence: functional endpoints and real-world outcomes to contextualize quality of life
From focus area to program
Each focus area forms the basis for a specific Target Product Profile (TPP). The insights gained from it flow iteratively into prototyping and the design of evidence pathways. This closed loop makes it possible to account for biological variance early and to map safety target parameters more precisely.
Patient group
/focus area
TPP
Formulation & delivery
Evidence pathway
Collaboration
We work together with hospitals, universities, and industry partners on program-specific profiles (from project scoping and endpoint definition to implementing suitable evidence formats).
Submit a collaboration inquiryScientific Lead
